Viking Therapeutics Stock Surges on Promising Obesity Drug Pipeline

Shares of Viking Therapeutics experienced a notable upswing this week, climbing 7.4% on Wednesday to close at $26.82. The catalyst for this positive movement was a freshly released corporate presentation that highlighted significant advancements within the company’s development pipeline, with a particular spotlight on its lead candidate, VK2735, for the treatment of obesity.

Investor Confidence Boosted by Strategic Updates

The investor presentation, made public on September 24, served to reinforce confidence by detailing the progress of Viking’s clinical programs. A key focus was VK2735, a dual GLP-1/GIP agonist. The subcutaneous formulation of this drug is now advancing through the Phase 3 VANQUISH program. Simultaneously, an oral tablet version has already demonstrated positive outcomes in the Phase 2 VENTURE trial.

The timing of this update proved strategic.... Read more...